Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer's Disease Study (LEADS). Alzheimer's & dementia : the journal of the Alzheimer's Association Cho, H., Mundada, N. S., Apostolova, L. G., Carrillo, M. C., Shankar, R., Amuiri, A. N., Zeltzer, E., Windon, C. C., Soleimani-Meigooni, D. N., Tanner, J. A., Heath, C. L., Lesman-Segev, O. H., Aisen, P., Eloyan, A., Lee, H. S., Hammers, D. B., Kirby, K., Dage, J. L., Fagan, A., Foroud, T., Grinberg, L. T., Jack, C. R., Kramer, J., Kukull, W. A., Murray, M. E., Nudelman, K., Toga, A., Vemuri, P., Atri, A., Day, G. S., Duara, R., Graff-Radford, N. R., Honig, L. S., Jones, D. T., Masdeu, J., Mendez, M., Musiek, E., Onyike, C. U., Riddle, M., Rogalski, E. J., Salloway, S., Sha, S., Turner, R. S., Wingo, T. S., Wolk, D. A., Koeppe, R., Iaccarino, L., Dickerson, B. C., La Joie, R., Rabinovici, G. D. 2023


We aimed to describe baseline amyloid-beta (Aß) and tau-positron emission tomograrphy (PET) from Longitudinal Early-onset Alzheimer's Disease Study (LEADS), a prospective multi-site observational study of sporadic early-onset Alzheimer's disease (EOAD).We analyzed baseline [18F]Florbetaben (Aß) and [18F]Flortaucipir (tau)-PET from cognitively impaired participants with a clinical diagnosis of mild cognitive impairment (MCI) or AD dementia aged < 65 years. Florbetaben scans were used to distinguish cognitively impaired participants with EOAD (Aß+) from EOnonAD (Aß-) based on the combination of visual read by expert reader and image quantification.243/321 (75.7%) of participants were assigned to the EOAD group based on amyloid-PET; 231 (95.1%) of them were tau-PET positive (A+T+). Tau-PET signal was elevated across cortical regions with a parietal-predominant pattern, and higher burden was observed in younger and female EOAD participants.LEADS data emphasizes the importance of biomarkers to enhance diagnostic accuracy in EOAD. The advanced tau-PET binding at baseline might have implications for therapeutic strategies in patients with EOAD.72% of patients with clinical EOAD were positive on both amyloid- and tau-PET. Amyloid-positive patients with EOAD had high tau-PET signal across cortical regions. In EOAD, tau-PET mediated the relationship between amyloid-PET and MMSE. Among EOAD patients, younger onset and female sex were associated with higher tau-PET.

View details for DOI 10.1002/alz.13453

View details for PubMedID 37690109